Net Cash Provided by (Used in) Financing Activities of OptimizeRx Corp from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
OptimizeRx Corp annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
  • OptimizeRx Corp Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $587,000, a 8.3% increase year-over-year.
  • OptimizeRx Corp annual Net Cash Provided by (Used in) Financing Activities for 2025 was $8,798,000, a 79% decline from 2024.
  • OptimizeRx Corp annual Net Cash Provided by (Used in) Financing Activities for 2024 was $4,911,000, a 117% decline from 2023.
  • OptimizeRx Corp annual Net Cash Provided by (Used in) Financing Activities for 2023 was $28,220,000.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

OptimizeRx Corp Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $8,798,000 -$3,887,000 -79% 01 Jan 2025 31 Dec 2025 10-K 12 Mar 2026 2025 FY
2024 $4,911,000 -$33,131,000 -117% 01 Jan 2024 31 Dec 2024 10-K 12 Mar 2026 2025 FY
2023 $28,220,000 +$47,170,777 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $18,950,777 -$92,875,731 -126% 01 Jan 2022 31 Dec 2022 10-K 15 Apr 2024 2023 FY
2021 $73,924,954 +$75,825,747 01 Jan 2021 31 Dec 2021 10-K 10 Mar 2023 2022 FY
2020 $1,900,793 -$24,082,321 -109% 01 Jan 2020 31 Dec 2020 10-K/A 10 Mar 2023 2021 FY
2019 $22,181,528 +$13,495,789 +155% 01 Jan 2019 31 Dec 2019 10-K 08 Mar 2021 2020 FY
2018 $8,685,739 +$9,075,739 01 Jan 2018 31 Dec 2018 10-K 26 Mar 2020 2019 FY
2017 $390,000 -$32,585 -9.1% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
2016 $357,415 -$4,703,861 -108% 01 Jan 2016 31 Dec 2016 10-K 08 Mar 2018 2017 FY
2015 $4,346,446 +$1,551,414 +56% 01 Jan 2015 31 Dec 2015 10-K 08 Mar 2017 2016 FY
2014 $2,795,032 +$2,795,032 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2016 2015 FY
2013 $0 $0 01 Jan 2013 31 Dec 2013 10-K 16 Sep 2015 2014 FY
2012 $0 -$442,500 -100% 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2013 2012 FY
2011 $442,500 -$1,716,250 -80% 01 Jan 2011 31 Dec 2011 10-K 12 Mar 2013 2012 FY
2010 $2,158,750 01 Jan 2010 31 Dec 2010 10-K 30 Mar 2012 2011 FY

OptimizeRx Corp Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $587,000 +$53,000 +8.3% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q1 2024 $640,000 -$509,000 -389% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q1 2023 $131,000 -$389,128 -151% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q1 2022 $258,128 -$69,922,606 -100% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q1 2021 $70,180,734 +$70,068,582 +62476% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q1 2020 $112,152 -$231,633 -67% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q1 2019 $343,785 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q1 2016 $357,415 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1
Q1 2014 $2,795,032 +$2,795,032 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1
Q1 2013 $0 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014 2014 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.